RT Book, Section
A1 Leavitt, Andrew D.
A1 Price, Erika Leemann
A2 Papadakis, Maxine A.
A2 McPhee, Stephen J.
A2 Rabow, Michael W.
A2 McQuaid, Kenneth R.
SR Print(0)
ID 1193158842
T1 Other Conditions Causing Thrombocytopenia
T2 Current Medical Diagnosis & Treatment 2023
YR 2023
FD 2023
PB McGraw-Hill Education
PP New York, NY
SN 9781264687343
LK accessmedicine.mhmedical.com/content.aspx?aid=1193158842
RD 2024/04/18
AB Drug-induced  thrombocytopenia  is  often  immune-mediated  but  can  also  be  due  to  marrow  suppression.  Table  14–7  lists  medications  associated  with  thrombocytopenia.  The  typical  presentation  of  drug-induced,  antibody-mediated  thrombocytopenia  is  severe  thrombocytopenia  and  mucocutaneous  bleeding  5–14  days  after  exposure  to  a  new  drug,  although  a  range  of  presentations  is  possible.  Discontinuation  of  the  offending  agent  leads  to  resolution  of  thrombocytopenia  within  3–7  days  in  most  cases,  but  recovery  kinetics  depend  on  rate  of  drug  clearance,  which  can  be  affected  by  liver  and  kidney  function.  Patients  with  severe  thrombocytopenia  should  be  given  platelet  transfusions  with  or  without  IVIG.  The  University  of  Oklahoma  Health  Sciences  center  maintains  a  useful  website  for  drug-induced  thrombocytopenia  (https://www.ouhsc.edu/platelets/).